Antihypertensives Flashcards
Thiazide
- loop diuretic (Na+ and K+ in for 2 Cl- out)
- inhibit Na+ absorption in DCT by blocking the NCC transporter
Toxicity of Diuretics
- low K+ (hypokalemia)
- metabolic alkalosis (increased delivery of K to the collecting ducts facilitates the exchange of K for H by the H/K exchangers on the intercalated alpha cells, resulting in loss of H [metabolic alkalosis])
- hyponatremia
- hypotension and decreased GFR
- metabolic alkalosis also due to increased proximal HCO3 reabsorption
- increased UA/gout
- hyperglycemia (inhibition of insulin release)
- hypercalemia (increased proximal calcium reabsoprtion)
- K-sparring agents –> hyperkalemia
- gynecomastia/sexual dysfunction (steroid receptor antagonism (spironolactone))
Prazosin
- adrenoreceptor antagonist
- alpha1 blockage in peripheral arterioles and venules
- useful for symptoms of BPH
Doxazosin
- adrenoreceptor antagonist
- alpha1 blockage in peripheral arterioles and venules
- useful for symptoms of BPH
Toxicity of Adrenoreceptor Antagonists
- dizziness
- headaches
- lassitude (a state of physical or mental weariness, lack of energy)
Hydralazine
- vasodilator
- given both PO and IV
- dilates arterioles, no veins
- effective in severe hypertension
- Toxicity: reflex increase in HR can cause myocardial ischemia; potential for lupus syndrome with pericarditis
Clonidine
- vasodilator
- centrally-acting
- alpha-2 agonist
- onset in 30-60 min
- useful in hypertensive urgencies
- very useful for treatment-resistant HTN
- decreases HR and PVR
- Toxicity: sudden withdrawal can result in sudden hypertensive crisis; sedation, dry mouth
Amlodipine
- vasodilator
- calcium-channel blocker
- can have cardiac depressant effects
Captopril
- ACE inhibitor
- inhibit peptidyl dipeptidase - affects RAAS and Kallikrein-kinin system
- Toxicity: ARF in pts with bilateral renal artery stenosis; dry cough; angioedema
- contraindicated in pregnancy
Enalapril
- ACE inhibitor
- inhibit peptidyl dipeptidase - affects RAAS and Kallikrein-kinin system
- Toxicity: ARF in pts with bilateral renal artery stenosis; dry cough; angioedema
- contraindicated in pregnancy
Losartan
- angiotensin-R blocker
- AT1 inhibitors; no effect on bradykinin
- Toxicity: similar effects to ACE inhibitor; less cough and angioedema
- contraindicated in pregnancy
Valsartan
- angiotensin-R blocker
- AT1 inhibitors; no effect on bradykinin
- Toxicity: similar effects to ACE inhibitor; less cough and angioedema
- contraindicated in pregnancy
Propranolol
- beta blocker
- non-selective
- decreased CO to decreased BP
- Benefits: reduce mortality post-MI; inhibits stimulation of renin release by catecholamines
- Toxicity: increased airway resistance; reduce IO pressure; impair recovery from hypoglycemia
Metoprolol
cardiac selective beta blocker
Atenolol
cardiac selective beta blocker
Pindolol
- partial agonist beta blocker
- decreased SVR (systemic vascular resistance)
- Benefits: does not change SVR and CO as much
Acebutaol
- partial agonist beta blocker
- decreased SVR (systemic vascular resistance)
- Benefits: does not change SVR and CO as much
Labetolol
- beta-blocking and vasodilating effects
- has both beta and alpha blocking action
- Benefits: reduced SVR without change in HR or CO
Carvedilol
- beta blocking and vasodilating effects
- has both beta and alpha blocking action
- Benefits: reduced SVR without change in HR or CO
- Toxicity: carvediol is effective in CHF and HTN
Esmolol
- beta-1 selective
- very rapid; given IV
- short half-life (~10 min)
Hydrochlorothiazide
- most common diuretic and antihypertensive prescribed (initial or add-on Rx)
- especially effective in patients with volume expanded/salt dependent/low-renin hypertension - including the elderly, diabetics, and blacks; pts w/ edema
Chlorthalidone
- diuretic
- more potent than HCTZ
- reduction in stroke, heart failure, coronary events
- more expensive to manufacture
Loop Diuretics
- reserved for CHF or resistant edema
- Na+ and K+ in for 2 Cl- out
K-sparing agents
- helpful for hypokalemic patients
- Na+ in for K+ out
- aldosterone antagonists
- may have heart failure benefits
Direct Vasodilators
- least frequently used for HTN
- most useful in severe or refractory HTN
- hypertensive emergencies like in pulmonary edema
- reflex increased SNS activity, increased HR and CO
- counters CO effect on HTN, so need to use in combination with beta-blocker
- BP lowering effect is non-renin dependent
- decreased renal perfusion leads to increased plasma renin activity and increased sodium-volume retention and edema
- “pseudotolerance” - almost always requires combination with loop diuretics and beta blockers
Minoxidil
- direct vasodilator
- very potent oral agent
- Adverse Effects: hypertrichosis (abnormal amount of hair growth), PEs, massive fluid retention, tachycardia
Nitroprusside
- direct vasodilator
- releases NO
- dilates arterioles and venules (decreased cardiac afterload and preload)
- Adverse Effect: structure of thiocynate is similar to cyanide and can result in cyanide toxicity
Alpha Adrenergic Receptors
- agonists (norepi>epinephrine)
- alpha-1 receptor (post-synaptic; mediates vasoconstriction)
- alpha-2 receptor (mostly pre-synaptic; inhibits norepinephrine release at peripheral and CNS sympathetic nerve terminals)
Alpha Receptor Antagonists
- inhibit the vasoconstrictor effects of norepi
- hemodynamic action (decreased TPR) similar to vasodilators, but with less tachycardia
- usually most effective in combination Rx
- may increase the sxs of HF as monotherapy
- Adverse Effects: postural hypotension, headache, edema
CNS-acting Sympathetic Inhibitors
- alpha-2 receptor AGONISTS in the medullary brainstem
- act in the CNS to decrease outflow of the SNS
Alpha Methyldopa
- CNS-acting sympathetic inhibitor
- alpha-2 agonist
- decreases outflow of the SNS
- given oral and IV
- used most commonly in pregnancy-associated HTN
- Adverse Effects: sedation; hepatitis and coombs pos hemolytic anemia
beta-1 Adrenergic Receptors
- increase cardiac SA node (increase heart rate)
- increase cardiac muscle contractility
- increase renin release (renal JGA cells)
beta-2 Adrenergic Receptors
- vascular smooth muscle (dilate)
- bronchial smooth muscle (bronchodilation)
- hepatocytes (glycogenolysis)
- pancreatic islet cells (insulin release)
Non-Selective Beta-Receptor Antagonists
- increases rick of bronchospasm, worsening diabetes, hyperlipidemia, risk of prolonged hypoglycemia, symptoms of PVD
- increased CNS adverse effects (fatigue, depression, ED) due to high lipid solubility
- may be superior for migraine prevention
beta-1 Selective Antagonists
- atenolol, metoprolol, bisoprolol
- inexpensive, may have fewer adverse effects
- most common type prescribed today
Vasodilatory Beta Blockers
- may have faster onset of BP reduction than other beta-blockers
- non-selective beta/alpha
- labetalol
- carvedilol
- RCT w/ carvedilol show long-term survival benefit in patients w/ CHF
- Nebivolol: beta-1 selective agent, releases NO
ISA (intrinsic sympathomimetic activity)
- pindolol, acebutolol
- may prevent extreme decreases HR at rest
- agonist and antagonist effects
- some pts on other antihypertensive meds have unusual degrees of bradycardia, so with a drug like pindolol you will have control of BP due to beta-blocker effect, but at night the heart rate will rise to normal levels
Indications for Beta Blockers (hypertension)
- often more effective in younger pts, those with signs of greater adrenergic activity or elevated plasma renin
- less BP reduction in low renin patients - blacks, elderly
- may have less stroke prevention in the elderly
Indications for Beta Blockers (cardiac disorders)
- tachyarrhythmias
- chronic LV dysfunction (metoprolol XL/carvedilol/bisoprolol)
- CAD: angina, acute coronary syndrome (ACS), post-MI
- hypertrophic subaortic stenosis
Indications for Beta Blockers (non-cardiac disorders)
- vascular (migraine) headache prevention
- essential tremor and performance anxiety
Calcium Channel Antagonists
- Ca channel antagonists bind the alpha-1 subunit of the L channel
- produce relaxation of VSM/myocardium; and slows SA and AV nodal transmission
- broad effectiveness as a single or combination Rx
- metabolically neutral: no effects on glucose, electrolytes, uric acid, lipids
- no renal, CNS, or pulmonary AEs
Diltiazem Hydrochloride
- calcium channel antagonist
- decreases heart rate
- decreases myocardial contractility
- decreases nodal conduction
- increases peripheral vasodilation
Verapamil Hydrochloride
- calcium channel antagonist
- decreases heart rate
- greatly decreases myocardial contractility (and CO)
- greatly decreases nodal conduction
- increases peripheral vasodilation
Nifedipine
- calcium channel antagonist
- increases heart rate
- slightly decreases or no effect at all on myocardial contractility
- NO EFFECT on nodal conduction
- greatly increases peripheral vasodilation
Nicardipine Hydrochloride
- calcium channel antagonist
- increases heart rate
- no effect on myocardial contractility
- no effect on nodal conduction
- greatly increases peripheral vasodilation
Calcium Channel Antagonist AEs
- edema, flushing, lightheadedness, constipation
- bradycardia and HF (uncommon)
- skin rash uncommon but can be serious
- diltiazem and verapamil (but not DHP) inhibit hepatic P450 isozymes
AT1 receptor
- vasoconstriction
- increased aldosterone levels
- proximal nephron increased Na+ retention
- JGA cells (inhibits renin release)
- cardiac and vascular tissue (profibrotic/remodeling)
Renin
- synthesis and release by the JGA cells, which are under feedback control
- decreased renal perfusion pressure leads to increased renin release
- increased renal SNS stimulation (JGA cell surface beta-1 receptors) leads to increases renin release (why we use beta blockers to help with HTN)
- angiotensin II negative feedback (JGA AT1 receptors) leads to decreases renin release (so we don’t release too much)
- increased distal tubular sodium content leads to increased renin release
Direct Renin Inhibitors
- inhibition of renin proteolytic action on its substrate and the formation rate of angiotensin I
- decreased PRA, angiotensin I, angiotensin II, aldosterone
- increases plasma renin level
ACE Inhibitors
- inhibition of the formation of angiotensin II from angiotensin I
- decrease angiotensin II and aldosterone levels
- increase levels of vasodilatory pepties (e.g. bradykinin)
- increase plasma renin levels
- increase plasma renin activity (PRA)
ARBs (angiotensin receptor blockers)
- blockage of angiotensin II (AT1) receptors at tissue sites
- decrease aldosterone levels
- increase plasma renin level, PRA, and angiotensin II levels
Aldosterone Antagonists
- blockage of mineralocorticoid/aldosterone receptors in the kidney and other sites
- Adverse Effect: hyperkalemia
Potential Adverse Effects of ACEi, ARB, DRI
- hyperkalemia (aldosterone inhibition)
- hypotension
- worsen renal insufficinecy (disproportionate glomerular efferent arterial vasodilation)
- fetal injury (angiotensin II important for fetal cell differentiation)… all inhibitors of RAA are contraindicated in pregnancy!
- ACEi - cough (5-10%) and angioedema (<1%)… ACE has many substrates (angiotensin I, bradykinin, substance P, neuropeptide Y, etc.)
Conditions that May Worsen with Certain Drug Therapies
- Pregnancy (RAA agents absolutely contraindicated!)
- Depression (beta blockers, central inhibitors)
- Sexual Dysfunction (beta blockers, central inhibitors, spironolactone)
- Asthma (beta blockers… especially non-selective)
- Gout (diuretics)
- Constipation (verapamil)
Conditions that May have Favorable Effects From BP Rx
- BPH (alpha blockers)
- essential tremor; performance anxiety; cardiac awareness (beta blockers)
- migraine headache (beta blockers, CCBs)
- osteoporosis (thiazides)
- kidney stones (thiazides)
- Raynaud’s Syndrome (DHP, CCBs)
- Chronic Diarrhea (verapamil… causes constipation)
- Hyponatremia/Hypercalcemia (loop diuretics (+IV saline)